Mark A. Hughes - Dec 22, 2021 Form 4 Insider Report for Hyperfine, Inc. (HYPR)

Role
Chief Operating Officer
Signature
/s/ John P. Condon, Attorney-in-Fact
Stock symbol
HYPR
Transactions as of
Dec 22, 2021
Transactions value $
$0
Form type
4
Date filed
12/23/2021, 08:46 PM
Next filing
Feb 11, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction HYPR Class A Common Stock Award +19.6K 19.6K Dec 22, 2021 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction HYPR Stock Option (right to buy) Award +21.3K 21.3K Dec 22, 2021 Class A Common Stock 21.3K $3.76 Direct F3, F4
transaction HYPR Stock Option (right to buy) Award +54K 54K Dec 22, 2021 Class A Common Stock 54K $3.76 Direct F5, F6
transaction HYPR Stock Option (right to buy) Award +3.28K 3.28K Dec 22, 2021 Class A Common Stock 3.28K $3.76 Direct F7, F8
transaction HYPR Stock Option (right to buy) Award +4.91K 4.91K Dec 22, 2021 Class A Common Stock 4.91K $3.27 Direct F9, F10
transaction HYPR Stock Option (right to buy) Award +60.6K 60.6K Dec 22, 2021 Class A Common Stock 60.6K $3.27 Direct F11, F12
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 In connection with the closing of the transactions contemplated by the Business Combination Agreement, dated as of July 7, 2021, by and among HealthCor Catalio Acquisition Corp. ("HealthCor"), Optimus Merger Sub I, Inc., a Delaware corporation and wholly owned subsidiary of HealthCor ("Merger Sub I"), Optimus Merger Sub II, Inc., a Delaware corporation and wholly owned subsidiary of HealthCor ("Merger Sub II"), Hyperfine, Inc.,
F2 a Delaware corporation ("Hyperfine"), and Liminal Sciences, Inc., a Delaware corporation ("Liminal"), pursuant to which Merger Sub I merged with and into Hyperfine (the "Hyperfine Merger"), with Hyperfine surviving the Hyperfine Merger as a wholly owned subsidiary of HealthCor, and Merger Sub II merged with and into Liminal (the "Liminal Merger" and, together with the Hyperfine Merger, the "Mergers"), with Liminal surviving the Liminal Merger as a wholly owned subsidiary of HealthCor (which changed its name to "Hyperfine, Inc.", the "Issuer"), these shares were received in exchange for 59,894 shares of Hyperfine common stock.
F3 The shares underlying this option vest as to 25% on September 30, 2020, with the remainder vesting in equal monthly installments, over the following three years, subject to Mr. Hughes's continued service through the applicable vesting date.
F4 Received in connection with the Mergers in exchange for a stock option to acquire 65,106 shares of Hyperfine common stock for $1.23 per share.
F5 The shares underlying this option vest as to 25% on December 31, 2020, with the remainder vesting in equal monthly installments, over the following three years, subject to Mr. Hughes's continued service through the applicable vesting date.
F6 Received in connection with the Mergers in exchange for a stock option to acquire 165,000 shares of Hyperfine common stock for $1.23 per share.
F7 The shares underlying this option vest as to 25% on December 31, 2020, with the remainder vesting in equal monthly installments, over the following three years, subject to Mr. Hughes's continued service through the applicable vesting date.
F8 Received in connection with the Mergers in exchange for a stock option to acquire 10,000 shares of Hyperfine common stock for $1.23 per share.
F9 The shares underlying this option vest in 48 equal monthly installments beginning on October 31, 2020, subject to Mr. Hughes's continued service through the applicable vesting date.
F10 Received in connection with the Mergers in exchange for a stock option to acquire 15,000 shares of Hyperfine common stock for $1.07 per share.
F11 The shares underlying this option vest in 48 equal monthly installments beginning on October 31, 2020, subject to Mr. Hughes's continued service through the applicable vesting date.
F12 Received in connection with the Mergers in exchange for a stock option to acquire 185,000 shares of Hyperfine common stock for $1.07 per share.